Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology.
Summary
Synthetic lethality describes a genetic interaction where two specific genetic alterations together impair cell viability, while either alteration alone is compatible with survival. This concept offers promising therapeutic avenues for targeting previously undruggable cancer pathways. High-throughput screening technologies have facilitated the discovery of novel druggable synthetic lethal vulnerabilities, particularly in DNA damage response and epigenetic alterations. Clinically approved PARP inhibitors have validated this approach in BRCA-mutant cancers. Emerging strategies targeting PRMT5, MAT2A, WRN, PKMYT1, and WEE1 are currently undergoing late preclinical or early clinical evaluation.
Analysis
Harnessing synthetic lethality represents a significant advancement in precision oncology, enabling the targeting of specific tumor cell vulnerabilities while sparing healthy cells. This strategy paves the way for developing novel therapies for resistant cancers or those lacking effective treatment options, particularly those with alterations in key pathways like DNA damage response or metabolism. The identification of predictive biomarkers associated with these interactions is crucial for guiding patient selection and optimizing clinical efficacy, thereby transforming the management of patients with hard-to-treat cancers.